| Mathurin, Philippe |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Recruiting | 2 | 50 | Europe, US | INT-787, Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Alcohol Associated Hepatitis | 12/24 | 03/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
NCT03695796: French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort) |
|
|
| Recruiting | N/A | 1000 | Europe | biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank | University Hospital, Angers | NAFLD | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 23 | Europe | nasopharyngeal Covid 19 RT-PCR | Centre Hospitalier Universitaire, Amiens, Centre Hospitalier-Universitaire Bondy, University Hospital, Bordeaux, Centre Hospitalier-Universitaire CLICHY, Centre Hospitalier Général CORBEIL-ESSONNE, CHU CRETEIL, University Hospital, Grenoble, University Hospital, Lille, CHU LYON, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Toulouse, CHU VILLEJUIF, Central Hospital, Nancy, France, Centre Hospitalier Universitaire de Nice, University Hospital, Montpellier | Hepatocellular Carcinoma, COVID-19 | 10/23 | 10/24 | | |
NASHSURG, NCT03472157: A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients |
|
|
| Recruiting | N/A | 100 | Europe | Lifestyle therapy, Bariatric surgery | University Hospital, Lille, Ministry of Health, France | Surgery, Obesity, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 03/26 | 03/26 | | |
| Recruiting | N/A | 800 | Europe | Blood draw for the laboratory assessment | ANRS, Emerging Infectious Diseases | Hepatitis D, Chronic, Hepatitis B, Chronic | 12/27 | 06/28 | | |
| Recruiting | N/A | 7500 | Europe | | University Hospital, Lille | Alcoholic Liver Disease | 03/32 | 03/32 | | |
| DERAMBURE, Philippe |
| Completed | 3 | 128 | Europe, Canada, US, RoW | Ganaxalone, Placebo | Marinus Pharmaceuticals, Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc. | Tuberous Sclerosis Complex | 09/24 | 10/24 | | |
| Terminated | 3 | 1 | Europe | Perampanel, Experimental group, Placebo, Control group | Assistance Publique - Hôpitaux de Paris | Epilepticus; Status, Focal Motor | 11/22 | 11/23 | | |
CENOR, NCT05747001: This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK |
|
|
| Completed | N/A | 319 | Europe | | Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research | Focal Onset Seizure, Epilepsy | 09/23 | 09/23 | | |
| Recruiting | N/A | 248 | Europe | Pharmacist intervention, Standard of care | University Hospital, Lille | Epilepsy | 10/23 | 10/23 | | |
| Recruiting | N/A | 100 | Europe | All included subjects | University Hospital, Lille | Temporal Lobe Epilepsy, Frontal Lobe Epilepsy, Others Subtypes | 03/27 | 03/27 | | |
ISEPEE, NCT06271785: Prognostic Value of High-resolution Electrical Source Imaging on the Success of Pediatric Focal Epilepsy Surgery |
|
|
| Recruiting | N/A | 120 | Europe | HR-EEG recording | University Hospital, Angers | Epilepsy in Children | 11/26 | 11/26 | | |
| Recruiting | N/A | 140 | Europe | Choice of VNS set of parameters based on the lowest PLI, EEG | Assistance Publique Hopitaux De Marseille | Epilepsy | 06/25 | 12/26 | | |
GALVANI GS-3, NCT06334952: Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic |
|
|
| Recruiting | N/A | 60 | Europe | transcranial direct current stimulation, Research MRI, EEG | Assistance Publique Hopitaux De Marseille, CRMBM-CEMEREM, Institut National de la Santé Et de la Recherche Médicale, France - LTSI, Neuroelectrics Corporation | Epilepsy, Drug Resistant Epilepsy | 12/26 | 11/27 | | |
HRVSAS, NCT06808464: New Approach in the Study of the Autonomic Nervous System Through Cardiac Variability in Sleep Apnea Syndrome. |
|
|
| Not yet recruiting | N/A | 97 | NA | | University Hospital, Lille | Sleep Apnea | 02/27 | 02/27 | | |
REPREO, NCT05609084: Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy |
|
|
| Recruiting | N/A | 214 | Europe | Speech therapy, Speech therapy assessment | Assistance Publique Hopitaux De Marseille | Epilepsy, Anomia, Temporal Lobe Epilepsy | 03/27 | 11/27 | | |
| Recruiting | N/A | 30 | Europe | Neuropsychological screening and high resolution EEG recording | University Hospital, Lille | Idiopathic Generalized Epilepsy | 04/25 | 04/25 | | |
NENUFAR, NCT06105645: Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy |
|
|
| Recruiting | N/A | 440 | Europe | DIXI Medical Microdeep® Micro- Macro Depth electrodes, Standard electrodes | University Hospital, Toulouse, Centre de recherche Cerveau et Cognition (CERCO), Dixi Medical | Epilepsy | 04/30 | 04/30 | | |
| Pattou, Francois |
DIABSURG, NCT01501201: Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients |
|
|
| Recruiting | 4 | 490 | Europe | Gastric By-Pass, RYGBP, optimized medical management | University Hospital, Lille | Obesity, Diabetes | 09/29 | 09/29 | | |
| Recruiting | N/A | 20000 | Europe | | University Hospital, Lille | Obesity, Glucose Intolerance, Diabetes | 01/25 | 01/25 | | |
| Vantyghem, Marie-Christine |
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy |
|
|
| Recruiting | 4 | 12 | Europe | Metreleptin | Amryt Pharma | Partial Lipodystrophy | 09/27 | 09/27 | | |
| Active, not recruiting | 2 | 30 | Europe, US | SPI-62 dose | Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc. | Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic | 12/24 | 12/25 | | |
OPALE, NCT03058185: Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies) |
|
|
| Recruiting | N/A | 800 | Europe | | Pitié-Salpêtrière Hospital, Institute of Myology, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France | Laminopathies, Emerinopathies | 07/33 | 07/33 | | |
APECED2, NCT03800056: Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2 |
|
|
| Recruiting | N/A | 30 | Europe | | University Hospital, Lille | Polyendocrinopathies, Autoimmune | 04/26 | 04/26 | | |
LINC6, NCT05382156: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome |
|
|
| Active, not recruiting | N/A | 206 | Europe, US | Osilodrostat, Isturisa | RECORDATI GROUP | Endogenous Cushing's Syndrome | 06/27 | 08/27 | | |
| Recruiting | N/A | 3000 | Europe | No intervention | European Georges Pompidou Hospital, Oscar - Filière Santé Maladies Rares | Hypoparathyroidism | 09/30 | 09/31 | | |
| Recruiting | N/A | 100 | Europe, US | Metreleptin | Aegerion Pharmaceuticals, Inc. | Generalised Lipodystrophy, Partial Lipodystrophy | 10/31 | 10/31 | | |
| Recruiting | N/A | 5000 | Europe, RoW | | University of Ulm, Sorbonne University, University Hospital, Lille, University of Cambridge, Endocrinology Research Centre, Moscow, University of Leipzig, University of Amsterdam, Dokuz Eylul University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Rome Tor Vergata, University of Pisa, University of Santiago de Compostela, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University Hospital Muenster, Szeged University, Centro Hospitalar do Porto, University Medical Centre Ljubljana, Medical University of Vienna, Ostschweizer Kinderspital | Lipodystrophy Acquired, Lipodystrophy Congenital | 01/68 | 01/68 | | |
| Belle, Eric Van |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
MESAMI2, NCT02462330: Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy |
|
|
| Completed | 2 | 39 | Europe | Autologous MSC from bone marrow, mesenchymal stem cells, Placebo comparator, Human Albumin | University Hospital, Toulouse | Chronic Myocardial Ischemia | 12/22 | 12/22 | | |
RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT |
|
|
| Completed | N/A | 307 | Europe | Optical Coherence Tomography (OCT) | University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT | In-stent Restenosis | 12/22 | 12/22 | | |
PiCSO-AMI-V, NCT04958421: A Study to Evaluate Safety and Feasibility of PiCSO Therapy in Patients With ST Elevation Inferior Wall Myocardial Infarction. |
|
|
| Terminated | N/A | 25 | Europe | PiCSO Impulse System | Miracor Medical SA | STEMI - ST Elevation Myocardial Infarction, Inferior Wall Myocardial Infarction | 02/23 | 02/23 | | |
| Active, not recruiting | N/A | 2001 | Europe | QFR-based diagnostic strategy, FFR-based diagnostic strategy | Aarhus University Hospital Skejby, Medis Medical Imaging Systems | Coronary Artery Disease | 07/23 | 12/25 | | |
| Completed | N/A | 60 | Europe | VALVOSFT intervention | Cardiawave SA, QbD Clinical | Aortic Valve Calcification, Aortic Valve Stenosis | 08/23 | 07/24 | | |
| Recruiting | N/A | 20 | Europe | Topaz TTVR System | TRiCares | Tricuspid Regurgitation | 12/24 | 05/29 | | |
| Completed | N/A | 172 | Europe | FFR-guided PCI and TAVI, CABG and SAVR | Maatschap Cardiologie Zwolle, Medtronic | Aortic Stenosis, Multi Vessel Coronary Artery Disease, TAVI, CABG, PCI, Fractional Flow Reserve | 06/24 | 06/24 | | |
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System |
|
|
| Active, not recruiting | N/A | 400 | Europe | Reducer System, Reducer | Neovasc Inc., Shockwave Medical, Inc. | Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina | 11/23 | 12/28 | | |
HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve |
|
|
| Recruiting | N/A | 30 | Europe, RoW | CLARITY | HighLife SAS | Mitral Regurgitation | 12/25 | 02/31 | | |
| Recruiting | N/A | 768 | Europe, RoW | Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site. | Meril Life Sciences Pvt. Ltd. | Aortic Valve Stenosis | 03/24 | 12/33 | | |
NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk |
|
|
| Recruiting | N/A | 120 | Europe, RoW | HighLife Transcatheter Mitral Valve Replacement | HighLife SAS, ICON plc | Mitral Regurgitation | 03/25 | 06/30 | | |
| Recruiting | N/A | 240 | Europe | Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score | Hospices Civils de Lyon | Severe Aortic Stenosis | 12/27 | 12/27 | | |
FAST III, NCT04931771: Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization |
|
|
| Recruiting | N/A | 2228 | Europe | vFFR guided revascularization, FFR guided revascularization | ECRI bv, Siemens Healthineers AG, Pie Medical Imaging | Coronary Artery Disease | 05/25 | 05/25 | | |
BEST, NCT05454150: Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 1862 | Europe | balloon-expandable valve, self-expanding valve | University Hospital, Lille, Ministry of Health, France | Aortic Valve Stenosis | 07/25 | 07/25 | | |
| Recruiting | N/A | 150 | Europe, Canada, RoW | Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI, redo-TAVR, Valve-in-Valve (ViV), TAV-in-TAV, TAVR-in-TAVR, Revalve | Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences | Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure | 09/25 | 12/26 | | |
| Recruiting | N/A | 944 | Europe | CT-ADP performed during TAVI procedure, No CT-ADP performed during TAVI procedure | University Hospital, Lille, Siemens Healthineers, France, Ministry of Health, France | Aortic Valve Stenosis, Aortic Valve Insufficiency | 12/25 | 12/25 | | |
MITRA-HR, NCT03271762: Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery |
|
|
| Recruiting | N/A | 330 | Europe, RoW | percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW, MITRACLIP, cardiac surgery | Nantes University Hospital, Ministère de la Santé, Abbott | Mitral Regurgitation | 03/27 | 05/28 | | |
| Recruiting | N/A | 400 | Europe, Canada, US | Evolut R/PRO bioprosthesis, Edwards Sapien S3/Ultra bioprosthesis | Erasmus Medical Center | Valve Heart Disease | 05/26 | 05/26 | | |
| FONTAINE, Pierre |
DIABSURG, NCT01501201: Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients |
|
|
| Recruiting | 4 | 490 | Europe | Gastric By-Pass, RYGBP, optimized medical management | University Hospital, Lille | Obesity, Diabetes | 09/29 | 09/29 | | |
ACTIDIANE, NCT03184662: Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes |
|
|
| Recruiting | N/A | 300 | Europe | HIPA, Counseling PA | Poitiers University Hospital, University Hospital, Bordeaux, University Hospital, Clermont-Ferrand, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Universitaire de Besancon, Hopital Lariboisière, Bichat Hospital, Centre Hospitalier Sud Francilien, University Hospital, Lille, Centre Hospitalier Universitaire de Nice, University Hospital, Caen, University Hospital, Toulouse, University Hospital, Tours, Nantes University Hospital, Groupe Hospitalier Pitie-Salpetriere, Hospices Civils de Lyon, University Hospital, Montpellier, University Hospital, Strasbourg, Central Hospital, Nancy, France, HOSPITAL, CHARTRES, University of Liege | Type2 Diabetes, Diabetic Kidney Disease | 09/23 | 12/23 | | |
| Recruiting | N/A | 34 | Europe | Exercise Training Procedure, Normal life procedure | University Hospital, Lille | Type1diabetes | 03/25 | 03/25 | | |
| PEREZ, Thierry |
OSCIVARI, NCT04087590: Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient |
|
|
| Recruiting | 2 | 35 | Europe | Formoterol-glycopyrronium co suspension (PT003) | University Hospital, Lille, AstraZeneca | Copd | 02/23 | 02/23 | | |
VARI-OSCIL, NCT06110403: Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness |
|
|
| Recruiting | 1/2 | 35 | Europe | TRIXEO AEROSPHERE | University Hospital, Lille, AstraZeneca | Copd | 09/25 | 09/25 | | |
| Completed | N/A | 120 | Europe | collection of data about each acute exacerbation of COPD | Centre Hospitalier Universitaire, Amiens, Clinique de l'Europe, Amiens, University Hospital, Lille | Pollution; Exposure, Chronic Obstructive Pulmonary Disease | 03/22 | 09/23 | | |
Steinert, NCT03764150: Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years |
|
|
| Recruiting | N/A | 160 | Europe | | University Hospital, Lille | Myotonic Dystrophy, Steinert | 09/23 | 09/23 | | |
MUCOSIM, NCT04010253: Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis |
|
|
| Recruiting | N/A | 42 | Europe | SIMEOX, Autogenic drainage | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | Cystic Fibrosis | 12/23 | 12/23 | | |
| Recruiting | N/A | 100 | Europe | Sample collecting, Lung function measure | University Hospital, Lille | Pulmonary Disease, Chronic Obstructive, Bacterial Infections | 07/28 | 07/28 | | |
| mariette, christophe |
PROBIOCOL, NCT02121743: Use of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy |
|
|
| Active, not recruiting | N/A | 80 | Europe | strattice, No strattice | Centre Hospitalier Universitaire, Amiens, LifeCell | Parastomal Hernia, Terminal Colostomy | 12/18 | 12/23 | | |
| Recruiting | N/A | 402 | Europe | treatment for ampullary adenocarcinoma, no other intervention name to add | Federation Francophone de Cancerologie Digestive | Ampullary Adenocarcinoma | 12/22 | 12/22 | | |
ADCI002, NCT01717924: Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma |
|
|
| Recruiting | N/A | 314 | Europe | peri-operative chemotherapy, Surgery first | University Hospital, Lille, Federation Francophone de Cancerologie Digestive, UNICANCER, Federation of Research in Surgery (FRENCH) | Signet Ring Cell Gastric Adenocarcinoma | 11/27 | 11/27 | | |
| Adenis, Antoine |
EPIC-1511, NCT02853474: Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy |
|
|
| Completed | 3 | 480 | Europe | Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score | Centre Oscar Lambret, Ligue contre le cancer, France, Région Nord-Pas de Calais, France, National Cancer Institute, France | Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer, Esophageal Cancer | 12/21 | 12/22 | | |
Esostrate, NCT02551458: Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy |
|
|
| Terminated | 2/3 | 188 | Europe | Systematic surgery, Surveillance and rescue surgery in cases of resectable loco-regional recurrence | Centre Hospitalier Universitaire Dijon | Epidermoid Carcinoma or, Adenocarcinoma of the Thoracic Oesophagus or, Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II), Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 | 03/23 | | | |
PROTECT, NCT02359968: PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer |
|
|
| Completed | 2 | 106 | Europe | FOLFOX, Fluorouracil, Oxaliplatin, Folinic acid, Elvorine, CarboP-pacliT, Carboplatine, paclitaxel | Centre Oscar Lambret, National Cancer Institute, France | Esophageal Neoplasms, Gastro-esophageal Junction Cancer | 01/21 | 02/24 | | |
NEONIPIGA, NCT04006262: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. |
|
|
| Recruiting | 2 | 32 | Europe | Nivolumab 10 MG/ML, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Localized Oesogastric Adenocarcimona, MSI and or dMMR | 06/24 | 06/24 | | |
|
FOLFIRINOX-R, NCT03828799: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer |
|
|
| Completed | 1/2 | 13 | Europe | Folfirinox + regorafenib | Institut du Cancer de Montpellier - Val d'Aurelle | Metastatic Colorectal Cancer | 12/21 | 11/24 | | |
| Recruiting | 1/2 | 747 | Europe | Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib | Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany | Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural | 12/24 | 12/25 | | |
NCT06539130: Medical Practices and Representations of People From Haiti in French Guiana |
|
|
| Completed | N/A | 83 | RoW | | Centre Hospitalier de Cayenne | Social Representations of Infectious Diseases | 05/23 | 05/23 | | |
| Recruiting | N/A | 30000 | Europe, RoW | Radical nephrectomy versus partial nephrectomy (according surgeon judgement) | University Hospital, Bordeaux | Kidney Cancer | 12/40 | 12/40 | | |
| Recruiting | N/A | 120 | Europe | Biological collection | Institut du Cancer de Montpellier - Val d'Aurelle | Pancreatic Cancer | 06/27 | 06/27 | | |
| Pattou, François |
TPIAT-01, NCT05116072: Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula |
|
|
| Recruiting | 1/2 | 36 | Europe | total pancreatectomy, intraportal islet autotransplantation | University Hospital, Lille, Ministry of Health, France | Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma | 02/25 | 02/25 | | |
| Active, not recruiting | 1/2 | 35 | Europe | Intramuscular Islet Autograft | University Hospital, Lille | Disorder of Endocrine Pancreas | 04/26 | 04/26 | | |
| Recruiting | N/A | 1000 | Europe | | University Hospital, Lille | Morbid Obesity, Bariatric Surgery Candidate | 01/24 | 01/24 | | |
| Recruiting | N/A | 390 | Europe | Control Group, Clinical visits conducted by a multidisciplinary team every year, Intervention Group, Clinical visits triggered by weight evolution | University Hospital, Lille, Ministry of Health, France | Bariatric Surgery, Long Term Follow-Up, Weight Regain | 03/24 | 03/24 | | |
| Recruiting | N/A | 20000 | Europe | | University Hospital, Lille | Obesity, Glucose Intolerance, Diabetes | 01/25 | 01/25 | | |
INTEGRA, NCT04194372: Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases |
|
|
| Recruiting | N/A | 10000 | Europe | | University Hospital, Lille | Metabolic Disease | 01/30 | 01/30 | | |
| Recruiting | N/A | 248 | Europe | Laparoscopic Mini-gastric bypass, Laparoscopic Roux-en-Y Gastric ByPass (RYGBP) | Hospices Civils de Lyon | Obesity | 09/24 | 09/24 | | |
| Semah, Franck |
| Recruiting | 3 | 88 | Europe | PET/CT with 18F-DOPA | Central Hospital, Nancy, France | Glioma | 12/25 | 10/26 | | |
| Paulin, Marion |
| Recruiting | N/A | 1100 | Europe | | University Hospital, Lille, Ministry of Health, France | Cerebrovascular Disorders, Dementia | 12/23 | 12/23 | | |
| Debarge, Véronique Houfflin |
APPART, NCT05625724: Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology |
|
|
| Recruiting | 3 | 1164 | Europe | Aspirin, Placebo | University Hospital, Toulouse | ART, Pre-Eclampsia | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 300 | Europe | Hydroxychloroquine, Placebo | University Hospital, Brest | Recurrent Miscarriage, First Trimester Abortion | 11/25 | 02/26 | | |
DANAO, NCT04911036: Study of the Effect of the Time of Diagnosis (Antenatal vs. Postnatal) on the Post-traumatic Reactions of Parents of Children Undergoing Oesophageal Atresia Surgery " |
|
|
| Recruiting | N/A | 240 | Europe | Questionnaires | University Hospital, Lille | Atresia, Esophageal | 05/23 | 05/23 | | |
| Rollin-Sillaire, Adeline |
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation |
|
|
| Recruiting | 2/3 | 280 | Europe, Canada, US, RoW | Remternetug, LY3372993, Matching Placebo (Remternetug) | Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors | Alzheimers Disease, Dementia, Alzheimers Disease, Familial | 03/34 | 08/34 | | |
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation |
|
|
| Recruiting | 2/3 | 280 | Europe, Canada, US, RoW | Remternetug (SC), Matching Placebo (Remternetug) | Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA) | Alzheimers Disease, Dementia, Alzheimers Disease, Familial | 03/34 | 08/34 | | |
| MACKOWIAK, Marie-Anne |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2 | 282 | Europe, Canada, US, RoW | GSK4527226, Placebo | GlaxoSmithKline, Alector Inc. | Alzheimer's Disease | 12/26 | 02/29 | | |
| Recruiting | N/A | 1100 | Europe | | University Hospital, Lille, Ministry of Health, France | Cerebrovascular Disorders, Dementia | 12/23 | 12/23 | | |
| DEFEBVRE, Luc |
| Recruiting | 3 | 152 | Europe | SPECT, PET | Zionexa | Parkinson Disease, Essential Tremor | 09/24 | 12/24 | | |
| Active, not recruiting | 3 | 134 | Europe | Apomorphine, Apokinon, Best Medical Treatment | Rennes University Hospital | Parkinson's Disease | 12/23 | 01/25 | | |
| Active, not recruiting | 2/3 | 110 | Europe, US | AMX0035, Placebo | Amylyx Pharmaceuticals Inc. | Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism | 04/26 | 11/29 | | |
NCT04691661: Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease |
|
|
| Recruiting | 2 | 40 | Europe | Radotinib HCl 50 mg, Radotinib, IY5511, Placebo | Il-Yang Pharm. Co., Ltd. | Parkinson Disease | 12/25 | 12/26 | | |
PIMPARK, NCT03947216: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. |
|
|
| Completed | 2 | 117 | Europe | Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound, Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Blood analysis, Cardiac monitoring | University Hospital, Strasbourg, France, NS-PARK, EUCLID Clinical Trial Platform, F-CRIN, ACADIA Pharmaceuticals Inc. | Parkinson Disease | 04/24 | 06/24 | | |
NCT03940872: Primary Parkinsonian Pain Diagnostic Questionnaire: Development and Validation of This Questionnaire |
|
|
| Completed | N/A | 227 | Europe | Self-questionnaire 3PDQ | University Hospital, Toulouse | Parkinson Disease | 12/22 | 12/22 | | |
| Recruiting | N/A | 76 | Europe | Erickson hypnosis | University Hospital, Lille, France Parkinson Association | Parkinson Disease, Chronic Pain | 08/24 | 08/24 | | |
RETRO-PIMPARK, NCT06754553: Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. |
|
|
| Not yet recruiting | N/A | 100 | Europe | Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Cardiac monitoring | University Hospital, Strasbourg, France, NS-PARK Network, EUCLID Clinical Trial Platform, F-CRIN | Parkinson Disease | 02/26 | 02/26 | | |
| VERMERSCH, Patrick |
| Recruiting | 3 | 800 | Europe, RoW | Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010 | AB Science | Progressive Multiple Sclerosis | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 72 | Europe | Ocrelizumab | Centre Hospitalier Universitaire de Nice | Multiple Sclerosis | 02/26 | 02/29 | | |
| Recruiting | N/A | 314 | Europe, Canada, US | MSCopilot® Detect mobile application | Ad scientiam | Multiple Sclerosis | 12/26 | 12/26 | | |
| Recruiting | N/A | 1000 | Europe, RoW | No intervention | Hospices Civils de Lyon | Sclerosis, Multiple, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders, Pregnancy Abnormal | 08/36 | 08/36 | | |
| LOUVET, Alexandre |
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites |
|
|
| Completed | 3 | 160 | Europe | Rifaximin, Placebo | Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA | Cirrhosis, Ascites, Peritonitis | 06/22 | 03/23 | | |
